Media

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization (CMA) for the medicinal product HEPCLUDEX® (bulevirtide, formally known as Myrcludex B).

ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression b

MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the General Session of the upcoming 2019 ILC meeting in Vienna